$Tonix Pharmaceuticals (TNXP.US)$ Watching Tonix Pharmaceuticals; Zacks Small-Cap Research Gives Stock $2.50 Price Valuation

$Inovio Pharmaceuticals (INO.US)$ Reuters· 1 min ago
New Retrospective Data Shows Half of Rrp Patients Treated With Ino-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

$Tonix Pharmaceuticals (TNXP.US)$ Many is selling，maybe will drop more

$Tonix Pharmaceuticals (TNXP.US)$ On December 3, 2024, Tonix Pharmaceuticals announced the hiring of Bradley Raudabaugh as VP of Marketing and Errol Gould, Ph.D., as VP of Medical Affairs. This strategic expansion aims to support the launch of TNX-102 SL for fibromyalgia management.The company submitted a New Drug Application (NDA) for TNX-102 SL to the FDA in October 2024, with acceptance expected in December 2024. If approved, TNX-102 SL would be the first new fibromyalgia drug in over ...

$Tonix Pharmaceuticals (TNXP.US)$ Tonix Pharmaceuticals Announces Expansion of Leadership Team With Two Strategic Hires

$Tonix Pharmaceuticals (TNXP.US)$ 🤑🚀

$Tonix Pharmaceuticals (TNXP.US)$ 🤑🤑🚀🚀

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings  Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

$Tonix Pharmaceuticals (TNXP.US)$ Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ:TNXP), joined Steve Darling from Proactive to unveil promising results at the ACR Convergence 2024 Annual Meeting from the company’s Phase 3 RESILIENT trial of its proprietary sublingual bedtime medication for fibromyalgia. The trial met its primary endpoint, achieving a statistically significant reduction in daily pain compared to a placebo.
Additionally, the treatment demonstr...